ライフサイエンスコーパス: extranodal

1 Twenty lesions (cutaneous = 10, nodal = 8, extranodal = 2) were treated to a mean of 35.4 Gy/2-3 Gy

2 Extranodal abdominal sites included liver (53%), small b

3 had atrioventricular dissociation ruling out extranodal accessory pathways, including atriofascicular

4 noclonal in 33%, 63%, and 56% of polymorphic extranodal and nodal LPD cases and DLBCL, respectively.

5 In earlier studies, we found that primary extranodal and widely disseminated aggressive non-Hodgki

6 tion and cloning of breakpoints in a case of extranodal ascitic B-cell lymphoma with a t(1;14)(q21;q3

7 ssociated with the development of aggressive extranodal B-cell non-Hodgkin's lymphomas.

8 e frequently (P = 0.02) compared to nodal or extranodal cases, alluding to distinct immunopathogeneti

9 extranodal sites (P = .005), both nodal and extranodal disease (P = .002), high International Progno

10 was associated with younger age (P=0.0016), extranodal disease (P=0.019), graft organ involvement (P

11 ese individuals have presented with advanced extranodal disease and CD4+ lymphocyte counts of less th

12 e significant predictors of poor OS and EFS: extranodal disease at first relapse, presence of mediast

13 f these factors also predicted for poor PFS (extranodal disease at time of first relapse and presence

14 Upstaging by extranodal disease in bone marrow (92), lung (11), or mu

15 Extranodal disease including grafted organ involvement w

16 Extranodal disease occurred at presentation in 70% and a

17 Extranodal disease was present in 30 patients (86%), wit

18 ents (87%) presented with nodal disease, but extranodal disease was present in 62%.

19 symptoms, bulky disease, advanced stage, or extranodal disease), relapse.

20 Of 19 complete responders, 84% had extranodal disease, 47% had CD4 < 100/muL, and 47% had V

21 on rate, B symptoms, large mediastinal mass, extranodal disease, and 3 or more lymph nodes) was stati

22 the study, 46% had stage II disease, 42% had extranodal disease, and 58% were more than 60 years of a

23 s (83%) had stage III to IV disease, 92% had extranodal disease, and 75% had > or = three sites of di

24 ed with improved outcome, whereas older age, extranodal disease, and acute graft-vs-host disease pred

25 y reported that remission duration < 1 year, extranodal disease, and B symptoms before salvage chemot

26 ICE that predicted for outcome: B symptoms, extranodal disease, and complete remission duration of l

27 All had extranodal disease, but only one had bone marrow involve

28 was present in 24%, and 76% of patients had extranodal disease.

29 maging should be considered in patients with extranodal disease.

30 nd to be more sensitive than CT at detecting extranodal disease.

31 sented with lymphadenopathy and 11% also had extranodal disease.

32 ation of the treatment response of nodal and extranodal diseases in patients with malignant lymphomas

33 lation in these tumors correlated with their extranodal dissemination status.

34 loped incorporating new histologic entities, extranodal dissemination, improved diagnostic methods, a

35 eased nodal disease and increased widespread extranodal dissemination.

36 med, the latter consisting of both nodal and extranodal DLBCL (nDLBCL and enDLBCL), to identify a "CN

37 DUSP4 is aberrantly methylated in nodal and extranodal DLBCL, irrespective of ABC or GCB subtype, re

38 3 siblings with PMBCL and their cousin with extranodal DLBCL.

39 ients with tumor size greater than 4.0 cm or extranodal extension >/= 2 mm experienced rates of isola

40 ne to three involved nodes and large tumors, extranodal extension >/= 2 mm, or inadequate axillary di

41 to undergo axillary lymph node dissection if extranodal extension (ENE) is present.

42 The extranodal extension (ENE) of nodal metastasis involves

43 Extranodal extension (HR, 1.41; 95% CI, 1.20 to 1.65; P

44 P < 0.001), SLN metastasis size (P < 0.001), extranodal extension (P < 0.001), tumor size (P = 0.001)

45 P <.001), tumor size (P <.001), and >/= 2-mm extranodal extension (P <.001) were also predictive of L

46 and P = .017, respectively), and absence of extranodal extension (P = .001 and P = .004, respectivel

47 breast cancer appears to be consistent with extranodal extension of tumor into perinodal fat.

48 imum SLN metastasis size and the presence of extranodal extension were recorded.

49 l sites, no B symptoms, mediastinal bulk, or extranodal extension) enrolled between March 3, 2000, an

50 for factors such as nodal size, laterality, extranodal extension, margin status, and adjuvant treatm

51 y tumor size, lymphovascular space invasion, extranodal extension, the number of involved SLNs, the n

52 We used microdissection of such extranodal follicles to analyze the colonizing T cells.

53 To examine their role in extranodal GC reactions, CD8 T cells were depleted in hu

54 while p73 modulated tumor dissemination and extranodal growth.

55 ients with EMZL (84%) presented with stage E-extranodal (IE), however only 16% had an advanced stage.

56 phoid microstructures that could be sites of extranodal immune activation.

57 Extranodal, intracranial disease is uncommon.

58 (+)IGF1R(+)CSF1R(+) LC phenotypes, including extranodal invasion and chemoresistance.

59 high-stage (III and IV) disease and 61% had extranodal involvement at presentation, including 25% wi

60 l EBV(+) diffuse large B-cell lymphomas with extranodal involvement developing in the context of graf

61 Frequently, there is extranodal involvement including the gastrointestinal tr

62 Extranodal involvement is more common than splenic or no

63 CNS involvement in PMLCL is associated with extranodal involvement other than bone marrow and may re

64 Other sites of extranodal involvement were observed in 50% of cases.

65 CD30-positivity, nodal disease with frequent extranodal involvement, advanced stage, and an excellent

66 years, 75% had stage III/IV disease, 67% had extranodal involvement, and 64% received rituximab.

67 , MYC rearrangement, protein expression, and extranodal involvement, and review our clinical practice

68 with B symptoms, and 40% of patients showed extranodal involvement.

69 s (25%) had staging laparotomy; 34 (19%) had extranodal involvement.

70 d is characterized by frequent cutaneous and extranodal involvement.

71 s; race (white/nonwhite); nodal involvement; extranodal involvement; number of extranodal sites; spec

72 However, a diagnosis of primary extranodal large B-cell lymphoma was returned.

73 and primary testicular lymphomas (PTLs) are extranodal large B-cell lymphomas (LBCLs) with inferior

74 d primary testicular lymphoma (PTL) are rare extranodal large B-cell lymphomas with similar genetic s

75 Sixteen of 21 cases of polymorphic extranodal LPD were classified as EBV(+) mucocutaneous u

76 id tissue (MALT) lymphoma is the most common extranodal lymphoid cell neoplasia; it frequently follow

77 of all tumors examined and clear evidence of extranodal lymphoid follicles with germinal center-like

78 The significance of this extranodal lymphoid neogenesis is unknown.

79 e and infiltrating lymphocytes in regulating extranodal lymphoid neogenesis.

80 id tissue (MALT) lymphoma is the most common extranodal lymphoid neoplasm.

81 mal cellular proliferations characterized as extranodal lymphoma and a proliferative mesenchymal lesi

82 This paper is part of the International Extranodal Lymphoma Study Group (IELSG) 26 prospective s

83 The International Extranodal Lymphoma Study Group (IELSG) 26 study was des

84 n the international randomized International Extranodal Lymphoma Study Group 19 (IELSG-19) trial.

85 The International Extranodal Lymphoma Study Group-32 (IELSG32) trial is an

86 ternational randomised phase 2 International Extranodal Lymphoma Study Group-32 (IELSG32) trial, HIV-

87 ry adrenal lymphomas are a very rare type of extranodal lymphoma, and they usually are found bilatera

88 TL) is a rare, clinically aggressive form of extranodal lymphoma.

89 Extranodal lymphomas can occur in almost every organ, an

90 ions, as data on efficacy in nodal and other extranodal lymphomas have been extrapolated to PTL.

91 ts for 0.4% of breast malignancies and 2% of extranodal lymphomas.

92 intestinal tract is the most common site for extranodal lymphomas.

93 d as the gold standard method for diagnosing extranodal lymphomas.

94 LC (73%) with REL amplification were primary extranodal lymphomas.

95 s a progression-associated marker of primary extranodal lymphomas.

96 2% of non-Hodgkin lymphomas (NHLs) and 8% of extranodal lymphomas.

97 and whether it is clinically different from extranodal MALT-type lymphoma, we compared the clinical

98 Extranodal manifestations were common in stage I and in

99 Extranodal marginal zone (MZ) B-cell lymphomas of the mu

100 homa Study Group classification of lymphoma, extranodal marginal zone B-cell lymphoma (MZL) of mucosa

101 4-year-old patient, who had liver granuloma, extranodal marginal zone B-cell lymphoma, and autoimmune

102 s the majority of follicle center lymphomas, extranodal marginal zone B-cell lymphomas, and immunocyt

103 d in the monocytoid and plasmacytic cells in extranodal marginal zone lymphoma (15 of 16 cases).

104 The most frequent subtype was extranodal marginal zone lymphoma (EMZL) (68.4% [180 of

105 The histologic subtype was extranodal marginal zone lymphoma (EMZL) in 51 patients

106 Extranodal marginal zone lymphoma (EMZL) was the most fr

107 hemistry were most consistent with pulmonary extranodal marginal zone lymphoma (ENMZL; Fig 2 ).

108 aldenstrom's macroglobulinemia (n = 2, 11%), extranodal marginal zone lymphoma (n = 2, 11%), plasmabl

109 enty-five percent of the cases reported were extranodal marginal zone lymphoma of mucosa-associated l

110 optimal systemic treatment of patients with extranodal marginal zone lymphoma of mucosa-associated l

111 re no widely accepted prognostic indices for extranodal marginal zone lymphoma of mucosa-associated l

112 genetic alteration among nodal, splenic, and extranodal marginal zone lymphoma types has yet to be de

113 Extranodal marginal zone lymphoma was the predominant (7

114 CL (37% low-grade non-Hodgkin lymphoma, 27% extranodal marginal zone lymphoma).

115 fusion transcripts were detected in 12 of 57 extranodal marginal zone lymphomas (21%), but in none of

116 Extranodal marginal zone lymphomas (EMZL) are the most c

117 gest that t(11;18)(q21;q21) is restricted to extranodal marginal zone lymphomas and that these tumors

118 le cell, five follicular, five Burkitt, five extranodal marginal zone lymphomas of mucosa-associated

119 comparison, 16 follicular lymphomas (FLs), 9 extranodal marginal zone lymphomas, and 8 reactive lymph

120 The most common subtypes were extranodal marginal-zone lymphoma (EMZL) (37% [n = 32]),

121 patients were alive and disease free without extranodal metastasis (median follow-up, 32.5 months).

122 stromal cells promotes CRC tumor growth and extranodal metastasis (P < 0.001).

123 Co-TICs showed increased tumor formation and extranodal metastasis capacities compared to unseparated

124 the LN stromal microenvironment in human CRC extranodal metastasis.

125 factors are lymph node (LN) involvement and extranodal metastasis.

126 ons may lead to effective therapy to prevent extranodal metastasis.

127 d HK cell support of CRC tumor formation and extranodal metastasis.

128 3) Extranodal mucosa associated lymphoid tissue lymphomas a

129 by DNA mutations or deletions in a panel of extranodal MZL (EMZL), nodal MZL (NMZL), and splenic MZL

130 Our series included nodal (n = 151), extranodal (n = 28), and primary splenic (n = 27) MCL ca

131 ic Islanders had a higher incidence of AITL, extranodal nasal-type natural killer/T-cell lymphoma and

132 The clinical outcome of extranodal natural killer T-cell lymphoma (ENKTL) has im

133 Extranodal natural killer T-cell lymphoma (NKTCL), nasal

134 enomic changes in blastic natural killer and extranodal natural killer-like T cell lymphoma with cuta

135 Extranodal natural killer-T-cell lymphoma (NKTCL) of nas

136 %) had anaplastic large cell; and 1 each had extranodal natural killer/T cell, angioimmunoblastic, an

137 anaplastic large-cell lymphoma (n = 2), and extranodal natural killer/T-cell lymphoma (n = 2).

138 ncy is different from that of other forms of extranodal NHL.

139 ntially critical role in the pathobiology of extranodal NK/T-cell lymphoma and aggressive NK-cell leu

140 ma, 14 adult T-cell leukemia/lymphoma and 44 extranodal NK/T-cell lymphoma that were further separate

141 Extranodal NK/T-cell NHL was also more common in CSA (P

142 -wide association study of 189 patients with extranodal NKTCL, nasal type (WHO classification criteri

143 inal tract and are the most common subset of extranodal non-Hodgkin lymphoma (NHL).

144 imary CNS lymphoma (PCNSL) is a rare form of extranodal non-Hodgkin lymphoma that is typically confin

145 ue (MALT) B-cell lymphoma is the most common extranodal non-Hodgkin lymphoma.

146 ry CNS lymphoma (PCNSL), an uncommon form of extranodal non-Hodgkin's lymphoma (NHL), has increased i

147 An unusual case of primary extranodal non-Hodgkin's lymphoma is described.

148 al nervous system lymphoma is a rare form of extranodal non-Hodgkin's lymphoma that is confined to th

149 On multivariate analysis, extranodal nonbone marrow disease and performance status

150 univariate analysis, bulky disease (>10 cm), extranodal nonbone marrow involvement, and poor performa

151 active lymphoid hyperplasia; (2) polymorphic extranodal or (3) polymorphic nodal lymphoproliferative

152 nlargement, 28% splenic involvement, and 81% extranodal or extrasplenic involvement.

153 e an aggressive clinical course and frequent extranodal presentation.

154 ng that REL amplification is associated with extranodal presentation.

155 substrate of AVNR during both intranodal and extranodal reentry.

156 ral, supraclavicular, internal mammary), and extranodal regions was documented.

157 nt natural history with frequent, continuous extranodal relapses.

158 involvement were involvement of more than 1 extranodal site (hazard ratio [HR], 2.60; 95% confidence

159 0037), involvement of more than one extranodal site (P = .0000), poor performance status (P

160 identified only involvement of more than one extranodal site (P = .0005) and an increased LDH (P = .0

161 Serum LDH and involvement of more than one extranodal site are independent risk factors for CNS rec

162 More than one extranodal site of disease and a second-line age-adjuste

163 Cancer Oncology Group performance status >1, extranodal sites >1, elevated lactate dehydrogenase, and

164 isease, lactic dehydrogenase (LDH) > normal, extranodal sites (ENSs) > one, and performance status (P

165 ent (P = .0005), the presence of one or more extranodal sites (P = .005), both nodal and extranodal d

166 present in 30 patients (86%), with multiple extranodal sites (two to seven) in 18 (51%).

167 The number of extranodal sites and the International Prognostic Index

168 Malignant lymphomas within inflamed extranodal sites exhibit a relatively high incidence of

169 Lymphoma arises at extranodal sites in which a pre-existing inflammatory re

170 Fifty-seven involved diverse extranodal sites including 14 stomach, 11 lung, 7 orbit,

171 it was recently reported that the number of extranodal sites is a more reliable predictor of CNS dis

172 ic phenotype associated with colonization of extranodal sites leads to CNS spread, possibly related t

173 ells that interact with malignant B cells at extranodal sites may influence both the development and

174 cology Group (ECOG) scale, more than 1, 23%; extranodal sites more than 1, 29%; mass more than 10 cm,

175 , serum lactate dehydrogenase, and number of extranodal sites of disease are all important prognostic

176 Only the number of extranodal sites was associated with occult CSF lymphoma

177 logy Group performance status, and number of extranodal sites were confirmed to be significant variab

178 llow-up, 22% of patients relapsed, mainly in extranodal sites, and 4% transformed to diffuse large B-

179 dehydrogenase, performance status, number of extranodal sites, and age, as previously reported.

180 marrow (BM), spleen, bulky lymph nodes, and extranodal sites, and in patients who had relapsed follo

181 mance score, lactic dehydrogenase, number of extranodal sites, B symptoms, size of largest mass, and

182 which frequently involve the skin and other extranodal sites, is often problematic because of the di

183 Age, stage, sex, B symptoms, number of extranodal sites, lactate dehydrogenase (LDH) levels, er

184 ancy has been increasingly observed in other extranodal sites, particularly in the skin.

185 (PMLCL) has a high propensity for involving extranodal sites, we investigated the frequency and patt

186 ), 91% were stage 4, and 69% had two or more extranodal sites.

187 pu in the development of AIDS-NHL at EC-rich extranodal sites.

188 that are induced by chronic inflammation in extranodal sites.

189 ficantly enriched in patients with 2 or more extranodal sites.

190 polymorphic disease, and the involvement of extranodal sites.

191 V-positive histology, and the involvement of extranodal sites.

192 volvement; extranodal involvement; number of extranodal sites; specific sites: bone marrow, liver, ki

193 High-risk features include extranodal spread of melanoma, more than two positive ly

194 d should be in the differential diagnosis of extranodal T-cell lymphoproliferations, including those

195 These cells accumulated in extranodal tissues and gave rise to clonal tumors recapi

196 Non-Hodgkin's lymphoma may arise in extranodal tissues within the head and neck region.

197 ization and homing of B cells to splenic and extranodal tissues, eventually driving malignant transfo

198 ymphoid organs, but disseminates early on in extranodal tissues.

199 hree possible disease forms in each patient: extranodal tumor, lymphadenopathy, and ascites.